 SYDNEY, Australia and FLORHAM PARK, N.J., Aug. 04, 2021 GLOBE NEWSWIRE -- Imugene Ltd Imugene ASX: IMU, a clinical stage immuno-oncology company and Celularity Inc. Celularity Nasdaq: CELU, a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, today announced they have entered into a research collaboration in 2021. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugenes CD19 oncolytic virus technology and Celularitys CD19 targeting allogeneic chimeric antigen receptor CAR T cellular therapy, CyCART-19, for the treatment of solid tumors. CyCART-19 is a placental-derived T-cell investigational therapy engineered with a CAR that is cryopreserved and will be available off-the-shelf. 